A 2-Stage Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Tablets in Healthy Subjects in a Double-blind, Placebo-controlled, Multiple-ascending-dose Stage and an Open-label, Single-dose, Crossover Food-effect Stage

Trial Profile

A 2-Stage Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Tablets in Healthy Subjects in a Double-blind, Placebo-controlled, Multiple-ascending-dose Stage and an Open-label, Single-dose, Crossover Food-effect Stage

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Dec 2016

At a glance

  • Drugs IW 1701 (Primary)
  • Indications Cardiovascular disorders
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Nov 2016.
    • 25 Oct 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top